Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 3.5% – What’s Next?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shares fell 3.5% during mid-day trading on Wednesday . The company traded as low as $1.09 and last traded at $1.09. 376,213 shares changed hands during mid-day trading, a decline of 65% from the average session volume of 1,068,293 shares. The stock had previously closed at $1.13.

Analysts Set New Price Targets

Several brokerages recently commented on RVPH. D. Boral Capital reaffirmed a “buy” rating and issued a $15.00 price target on shares of Reviva Pharmaceuticals in a research note on Tuesday, January 21st. HC Wainwright dropped their target price on shares of Reviva Pharmaceuticals from $14.00 to $11.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. Roth Mkm initiated coverage on shares of Reviva Pharmaceuticals in a report on Friday, January 10th. They set a “buy” rating and a $7.00 price target for the company. Maxim Group raised shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research note on Friday, January 10th. Finally, Roth Capital upgraded shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $11.40.

Reviva Pharmaceuticals Trading Down 3.5 %

The stock has a market cap of $36.45 million, a P/E ratio of -0.98 and a beta of -0.09. The business’s fifty day simple moving average is $1.56 and its 200 day simple moving average is $1.48.

Institutional Trading of Reviva Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Tang Capital Management LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 4th quarter valued at $308,000. Cornerstone Select Advisors LLC bought a new stake in Reviva Pharmaceuticals during the 4th quarter worth about $32,000. Ameriprise Financial Inc. acquired a new position in Reviva Pharmaceuticals during the 4th quarter valued at about $84,000. Tower Research Capital LLC TRC boosted its stake in shares of Reviva Pharmaceuticals by 848.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 26,775 shares of the company’s stock valued at $48,000 after purchasing an additional 23,953 shares during the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Reviva Pharmaceuticals during the 4th quarter worth approximately $45,000. 63.18% of the stock is owned by institutional investors.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.